PR Newswire Asia's news > Health Care/Hospital

 < Previous page   |   Title only   |   Print    Next page > 
     
High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease
CorrectSequence Therapeutics Reports Positive 15-Month Follow-Up Data for CS-206 ...
2026-06-02T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Phenomenex Launches Endrix Long Life Columns, Redefining Column Durability and Method Reliability
Redefined Column Durability and Method Reliability ...
2026-06-01T    Biotechnology   Chemical   Health Care/Hospital   Medical/Pharmaceuticals 
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business
Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs. Transaction includes sevasemten, a late-stage investigational treatment for ...
2026-06-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
3billion Launches 3B-NEO, a Genomic Newborn Screening Service Covering 595 Clinically Actionable Genetic Conditions
Screens 595 carefully selected genes associated with childhood-onset conditions where early intervention may improve outcomes Designed for maternity hospitals, obstetrics practices, newborn care providers, ...
2026-06-01T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical Equipment 
Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research
Delivers up to 20x improvement in MS/MS sensitivity and 2x faster acquisition speeds, enabling deeper biological insight for next-generation multiomics, therapeutic, and high-throughput workflows. ...
2026-06-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics
>10x step-change in MS/MS sensitivity paired with multipass Cyclicâ„¢ Ion Mobility Spectrometry (IMS) reveals subtle biological differences for earlier, previously unattainable detection of disease signals. ...
2026-06-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
/C O R R E C T I O N -- Ranok Therapeutics/
In the news release, Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic Non-Small Cell Lung Cancer Presented At ...
2026-06-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Biond Biologics and Guangzhou-Israel Biotechnology Fund ("GIBF") Announce Closing of $8 Million Investment and Collaboration
Biond Biologics and Guangzhou-Israel Biotechnology Fund (GIBF) Announce Strategic Investment and Joint Venture to Advance First-in-Class Oncology Programs in China ...
2026-06-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Ebola disease in Democratic Republic of Congo: MSF scales up response to a rapidly evolving outbreak
HONG KONG , June 1, 2026 /PRNewswire/ -- In eastern Democratic Republic of Congo (DRC), people have been living through insecurity and with an under-resourced health system for years. The Ebola disease ...
2026-06-01T    Health Care/Hospital   Infectious Disease Control   Medical/Pharmaceuticals 
Haisco Announces Licensing and Research Collaboration Agreement with Lilly to Develop Innovative Medicines Across Multiple Therapeutic Areas
SILICON VALLEY, Calif. and BEIJING , June 1, 2026 /PRNewswire/ -- On May 29, 2026, Haisco Pharmaceutical Group Co., Ltd. ("Haisco") (Ticker Code: 002653) announced a licensing and research ...
2026-06-01T    Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.